Secukinumab is usually well tolerated during 5 years of treatment, the most commonly reported adverse events is nasopharyngitis, Secukinumab is treating unused TNF inhibitors in patients with active AS an effective therapy, inadequate response to TNF inhibitors or intolerance patients provides a useful therapeutic option.[44]. The gene discussed is TNF; the disease is nasopharyngitis.